This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of Calgary directory, so their courses and email address may be missing. Find their university profile.
Latest papers
Daratumumab, lenalidomide, and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: MAIA final survival analysis.
Leukemia · 2026
TNFRSF17 genomic profiling guides retreatment with alternative BCMA-directed immunotherapies in multiple myeloma.
Blood advances · 2026
Infections in patients receiving daratumumab for newly diagnosed multiple myeloma: a pooled analysis of MAIA and ALCYONE.
Blood advances · 2026 · first author
Latest funding
- $522,880
Bortezomib mediated BRCAness in Myeloma cells: novel therapeutic approach combining PARP1-2 and 26S proteasome inhibitors.
CIHR · 2012 · Nominated PI
Bortezomib mediated BRCAness in Myeloma cells: novel therapeutic approach combining PARP1-2 and 26S proteasome inhibitors.
CIHR · 2011 · Nominated PI
- $105,000
Influence of microRNA on Resistance to Proteasome Inhibitors in Multiple Myeloma
CIHR · 2011 · Supervisor
50 publications.
Daratumumab, lenalidomide, and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: MAIA final survival analysis.
Facon T, Kumar SK, Orlowski RZ, Bahlis N, Moreau P, Goldschmidt H, Basu S, Hulin C, Zweegman S, Weisel K, Perrot A, Jacquet C, Raje N, Manier S, Chari A, Hansson M, Mohty M, Delforge M, Plesner T, Cook G, Leleu X, Quach H, Venner CP, Tiab M, Macro M, Frenzel L, Wang G, Pei H, Bolyard K, Carson R, Borgsten F, Usmani SZ
TNFRSF17 genomic profiling guides retreatment with alternative BCMA-directed immunotherapies in multiple myeloma.
Podvin B, Lee H, Tilmont R, Decool G, Cavalieri D, Demarquette H, Gower N, Nudel M, Bourgeois E, Robu D, Tricot S, Arib I, Cacheux V, Caillault-Venet A, Preudhomme C, Duployez N, Facon T, Neri P, Bahlis N, Manier S
Infections in patients receiving daratumumab for newly diagnosed multiple myeloma: a pooled analysis of MAIA and ALCYONE.
Bahlis N, Facon T, San-Miguel J, Usmani SZ, Dimopoulos MA, Moreau P, Zweegman S, Perrot A, Manier S, Chari A, Raje N, Orlowski RZ, Goldschmidt H, Basu S, Hulin C, Weisel K, Mohty M, Leleu X, Plesner T, Jakubowiak A, Cook G, Quach H, Venner CP, Cavo M, Ngo M, Bolyard K, Carson R, Borgsten F, Mateos MV, Kumar SK
Comparative Efficacy of Talquetamab vs. Real-World Physician's Choice of Treatment in Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma: Updated Analyses of MonumenTAL-1 vs. LocoMMotion/MoMMent.
Einsele H, Moreau P, Bahlis N, Bhutani M, Vincent L, Karlin L, Perrot A, Goldschmidt H, van de Donk NWCJ, Ocio EM, Martínez López J, Rodríguez-Otero P, Dytfeld D, Jakubowiak A, Schinke C, Besemer B, Anguille S, Manier S, Rasche L, Teipel R, Scheid C, Pawlyn C, Cavo M, Diels J, Ghilotti F, Lau BW, Renaud T, Orel O, Ong F, Ramos DF, Ammann E, Parekh T, Albrecht C, Weisel K, Mateos MV
International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma
Costa LJ, Banerjee R, Mian H, Weisel K, Bal S, Derman BA, Htut MM, Nagarajan C, Rodriguez C, Richter J
Daratumumab plus lenalidomide/dexamethasone in untreated multiple myeloma: analysis of key subgroups of the MAIA study.
Moreau P, Facon T, Usmani SZ, Bahlis N, Raje N, Plesner T, Orlowski RZ, Basu S, Nahi H, Hulin C, Quach H, Goldschmidt H, O'Dwyer M, Perrot A, Venner CP, Weisel K, Tiab M, Macro M, Frenzel L, Leleu X, Wang G, Pei H, Krevvata M, Carson R, Borgsten F, Kumar SK
Immunophenotypic changes in the tumor and tumor microenvironment during progression to multiple myeloma.
Bergiers I, Köse MC, Skerget S, Malfait M, Fourneau N, Ellis JC, Vanhoof G, Smets T, Verbist B, De Maeyer D, Van Houdt J, Van der Borght K, Verona R, Heidrich B, Kurth W, Delforge M, Meuleman N, Van Droogenbroeck J, Vlummens P, Heuck CJ, Beguin Y, Bahlis N, Casneuf T, Caers J
Biallelic antigen escape is a mechanism of resistance to anti-CD38 antibodies in multiple myeloma.
Diamond B, Baughn L, Poorebrahim M, Poos AM, Lee H, Kaddoura M, Wiedmeier-Nutor JE, Durante M, Otteson G, Jevremovic D, Tang H, Fröhling S, Baertsch MA, Papadimitriou M, Ziccheddu B, Jelinek T, Lemoine C, Rak A, Green DJ, Landgren O, Neri P, Bergsagel L, Braggio E, Kumar S, Raab MS, Fonseca R, Bahlis N, Weinhold N, Maura F
Daratumumab/lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes.
Facon T, Moreau P, Weisel K, Goldschmidt H, Usmani SZ, Chari A, Plesner T, Orlowski RZ, Bahlis N, Basu S, Hulin C, Quach H, O'Dwyer M, Perrot A, Jacquet C, Venner CP, Raje N, Tiab M, Macro M, Frenzel L, Leleu X, Cook G, Wang G, Pei H, Krevvata M, Carson R, Borgsten F, Kumar SK
Comparative Efficacy of Talquetamab vs. Current Treatments in the LocoMMotion and MoMMent Studies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma.
Einsele H, Moreau P, Bahlis N, Bhutani M, Vincent L, Karlin L, Perrot A, Goldschmidt H, van de Donk NWCJ, Ocio EM, Martinez-Lopez J, Rodríguez-Otero P, Dytfeld D, Diels J, Strulev V, Haddad I, Renaud T, Ammann E, Cabrieto J, Perualila N, Gan R, Zhang Y, Parekh T, Albrecht C, Weisel K, Mateos MV
Bortezomib mediated BRCAness in Myeloma cells: novel therapeutic approach combining PARP1-2 and 26S proteasome inhibitors.
Principal investigators: Bahlis, Nizar J
Keywords: Multiple Myeloma; Parp And Dna Repair; Phase I Clinical Trial; Proteasome Inhibitors
Bortezomib mediated BRCAness in Myeloma cells: novel therapeutic approach combining PARP1-2 and 26S proteasome inhibitors.
Principal investigators: Bahlis, Nizar J
Keywords: Multiple Myeloma; Parp And Dna Repair; Phase I Clinical Trial; Proteasome Inhibitors
Influence of microRNA on Resistance to Proteasome Inhibitors in Multiple Myeloma
Principal investigators: Stebner, Erin M
Keywords: Cancer Genetics; Fluorescent In Situ Hybridization; Gene Expression Profiling; Hematology; In Vitro Studies; In Vivo Studies; Microarray; Microrna; Multiple Myeloma; Qrt-Pcr
Influence of microRNA on drug resistant and sensitive multiple myeloma cells.
Principal investigators: Stebner, Erin M
Keywords: Gene Expression Profiling; In Vitro Studies; In Vivo Studies; Microarray; Microrna; Multiple Myeloma; Qrt-Pcr; Rna Extraction; Sirna; Tissue Collection
From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.
Frequent collaborators
- Michael Sebag and Donna Reece: 25 shared papers
- Donna Reece and Suzanne Trudel: 20 shared papers
- Hira Mian and Donna Reece: 19 shared papers
- Hira Mian and Michael Sebag: 18 shared papers
- Mathieu Lupien and Marco Gallo: 5 shared papers
- Hira Mian and Suzanne Trudel: 4 shared papers
- Michael Sebag and Suzanne Trudel: 3 shared papers
- Mathieu Lupien and Sorana Morrissy: 3 shared papers
- Nizar Bahlis and Karen Kopciuk: 2 shared papers
- Nizar Bahlis and Sorana Morrissy: 2 shared papers
- Nizar Bahlis and Mona Shafey: 2 shared papers
- Marco Gallo and Sorana Morrissy: 2 shared papers
- Hira Mian and Nizar Bahlis: 1 shared paper
- Michael Sebag and Nizar Bahlis: 1 shared paper
- Nizar Bahlis and Mathieu Lupien: 1 shared paper
- Nizar Bahlis and Donna Reece: 1 shared paper
- Nizar Bahlis and Steven Jones: 1 shared paper
- Nizar Bahlis and Marco Gallo: 1 shared paper
- Nizar Bahlis and Suzanne Trudel: 1 shared paper
- Mathieu Lupien and Steven Jones: 1 shared paper
- Steven Jones and Marco Gallo: 1 shared paper
- Medicine
- Oncology
- Hematology-Oncology
- Biochemistry and Molecular Biology
- Medical Biophysics
- Genetics
- Other
Co-authors at University of Calgary, colored by department. Thicker lines mean more shared papers; select anyone to open their profile and their own map.
Karen Kopciuk
Oncology
2 shared papers, latest 2013
Sorana Morrissy
Medicine
2 shared papers, latest 2021
Mona Shafey
Medicine
2 shared papers, latest 2020
Mathieu Lupien
Medical Biophysics
1 shared papers, latest 2021
Suzanne Trudel
Faculty
1 shared papers, latest 2024
Marco Gallo
Biochemistry and Molecular Biology
1 shared papers, latest 2021
Donna Reece
Faculty
1 shared papers, latest 2020
Steven Jones
Genetics
1 shared papers, latest 2021
Hira Mian
Oncology
1 shared papers, latest 2025
Michael Sebag
Medicine
1 shared papers, latest 2021
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.